CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Mar 31, 2032 → May 31, 2032
See other at-risk trials from Washington University School of Medicine

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Start date: Aug 31, 2026 to Oct 31, 2026
    • Primary endpoints: details revised at 4 of 9 entries
    • Primary and study completion pushed from Mar 31, 2032 to May 31, 2032
    • Eligibility criteria expanded, about 7 words
    • Site details revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).
Trial Details
NCT Number NCT07659678
Lead Sponsor Washington University School of Medicine
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma HNSCC
Related terms Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence, Squamous Cell Carcinoma of Head and Neck
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov